Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective

In our 2020 consensus paper, we devised ten recommendations for conducting Complex Innovative Design (CID) trials to evaluate cancer drugs. Within weeks of its publication, the UK was hit by the first wave of the SARS-CoV-2 pandemic. Large CID trials were prioritised to compare the efficacy of new a...

Descripción completa

Detalles Bibliográficos
Autores principales: Blagden, Sarah P., Yu, Ly-Mee, Ellis, Stephanie, Hughes, Helen, Shaaban, Abeer, Fennelly-Barnwell, Jonathan, Lythgoe, Mark P., Cooper, Alison M., Maignen, Francois M., Buckland, Sean W., Kearns, Pamela R., Brown, Louise C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702707/
https://www.ncbi.nlm.nih.gov/pubmed/36434156
http://dx.doi.org/10.1038/s41416-022-02051-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702707/
https://www.ncbi.nlm.nih.gov/pubmed/36434156
http://dx.doi.org/10.1038/s41416-022-02051-7

Ejemplares similares